ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1659

Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
Abstract Number: 1160

Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
Abstract Number: 2656

Short-Term Effectiveness of a Walk with Ease Program Delivered by Telephone on Arthritis-Related Symptoms, Function, and Physical Activity
Abstract Number: 0443

Significance of anti-Ro52 Antibody in Pregnancy Complicated with Anti-SS-A Antibody Positive Rheumatic Disease Patients
Abstract Number: 1440

Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors
Abstract Number: 0502

Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
Abstract Number: 2278

Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Abstract Number: 1148

Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis
Abstract Number: 0096

Simultaneous Contribution of Brain-Intrinsic and Peripheral Disease Mechanisms to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus (NPSLE)
Abstract Number: 1703

Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Abstract Number: 1426

Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis
Abstract Number: 1692

Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Abstract Number: 0952

Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population
Abstract Number: 0052

Single Cell RNA-sequencing Analysis Revealed Peripheral Blood and Synovial Alterations of Dendritic Cells in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].